Search research articles
Contact Us
Filters
Showing results (191-200 of 203) with videos related to
Page
of 21
Sort By:
JHEP Reports : Innovation in Hepatology
|
January 26, 2024
A meta-analysis and real-world cohort study on the sex-related differences in efficacy and safety of immunotherapy for hepatocellular carcinoma
Lorenz Balcar, Bernhard Scheiner, Claudia Angela Maria Fulgenzi, et al.
European Journal of Cancer (Oxford, England : 1990)
|
April 24, 2026
Determinants of long-term survival from atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma
Pei-Chang Lee, Alessio Cortellini, Bernardo Stefanini, et al.
Gut
|
July 5, 2022
Genetic variation in <i>TERT</i> modifies the risk of hepatocellular carcinoma in alcohol-related cirrhosis: results from a genome-wide case-control study
Stephan Buch, Hamish Innes, Philipp Ludwig Lutz, et al.
Hepatology (Baltimore, Md.)
|
July 19, 2024
Hepatic decompensation is the major driver of mortality in patients with HCC treated with atezolizumab plus bevacizumab: The impact of successful antiviral treatment
Ciro Celsa, Giuseppe Cabibbo, Claudia Angela Maria Fulgenzi, et al.
JAMA Oncology
|
July 18, 2024
Immunotherapy vs Best Supportive Care for Patients With Hepatocellular Cancer With Child-Pugh B Dysfunction
Claudia Angela Maria Fulgenzi, Bernhard Scheiner, Antonio D'Alessio, et al.
Hepatology (Baltimore, Md.)
|
December 7, 2024
Outcome and management of patients with hepatocellular carcinoma who achieved a complete response to immunotherapy-based systemic therapy
Bernhard Scheiner, Beodeul Kang, Lorenz Balcar, et al.
Journal of Hepatology
|
June 15, 2026
A myeloid immunosuppressive phenotype defines primary refractoriness to atezolizumab Plus bevacizumab in hepatocellular caarcinoma
Pasquale Lombardi, Erik Ramon-Gil, Rabial Q Raja, et al.
JHEP Reports : Innovation in Hepatology
|
March 10, 2025
Evaluation of prognostic scores in patients with HCC undergoing first-line immunotherapy with atezolizumab and bevacizumab
Simon Johannes Gairing, Philipp Mildenberger, Jennifer Gile, et al.
The Lancet. Digital Health
|
February 13, 2026
The use of advanced machine learning to predict outcomes after atezolizumab plus bevacizumab for advanced hepatocellular carcinoma: a retrospective cohort study
Mathew Vithayathil, Giulia Francesca Manfredi, Antonio D'Alessio, et al.
Journal of Hepatology
|
November 16, 2023
Characteristics and outcomes of immunotherapy-related liver injury in patients with hepatocellular carcinoma versus other advanced solid tumours
Ciro Celsa, Giuseppe Cabibbo, Claudia A M Fulgenzi, et al.
Page
of 21
Search research articles
Search
Showing results (191-200 of 203) with videos related to
Sort By:
Page
of 21
JHEP Reports : Innovation in Hepatology
|
January 26, 2024
A meta-analysis and real-world cohort study on the sex-related differences in efficacy and safety of immunotherapy for hepatocellular carcinoma
Lorenz Balcar, Bernhard Scheiner, Claudia Angela Maria Fulgenzi, et al.
European Journal of Cancer (Oxford, England : 1990)
|
April 24, 2026
Determinants of long-term survival from atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma
Pei-Chang Lee, Alessio Cortellini, Bernardo Stefanini, et al.
Gut
|
July 5, 2022
Genetic variation in <i>TERT</i> modifies the risk of hepatocellular carcinoma in alcohol-related cirrhosis: results from a genome-wide case-control study
Stephan Buch, Hamish Innes, Philipp Ludwig Lutz, et al.
Hepatology (Baltimore, Md.)
|
July 19, 2024
Hepatic decompensation is the major driver of mortality in patients with HCC treated with atezolizumab plus bevacizumab: The impact of successful antiviral treatment
Ciro Celsa, Giuseppe Cabibbo, Claudia Angela Maria Fulgenzi, et al.
JAMA Oncology
|
July 18, 2024
Immunotherapy vs Best Supportive Care for Patients With Hepatocellular Cancer With Child-Pugh B Dysfunction
Claudia Angela Maria Fulgenzi, Bernhard Scheiner, Antonio D'Alessio, et al.
Hepatology (Baltimore, Md.)
|
December 7, 2024
Outcome and management of patients with hepatocellular carcinoma who achieved a complete response to immunotherapy-based systemic therapy
Bernhard Scheiner, Beodeul Kang, Lorenz Balcar, et al.
Journal of Hepatology
|
June 15, 2026
A myeloid immunosuppressive phenotype defines primary refractoriness to atezolizumab Plus bevacizumab in hepatocellular caarcinoma
Pasquale Lombardi, Erik Ramon-Gil, Rabial Q Raja, et al.
JHEP Reports : Innovation in Hepatology
|
March 10, 2025
Evaluation of prognostic scores in patients with HCC undergoing first-line immunotherapy with atezolizumab and bevacizumab
Simon Johannes Gairing, Philipp Mildenberger, Jennifer Gile, et al.
The Lancet. Digital Health
|
February 13, 2026
The use of advanced machine learning to predict outcomes after atezolizumab plus bevacizumab for advanced hepatocellular carcinoma: a retrospective cohort study
Mathew Vithayathil, Giulia Francesca Manfredi, Antonio D'Alessio, et al.
Journal of Hepatology
|
November 16, 2023
Characteristics and outcomes of immunotherapy-related liver injury in patients with hepatocellular carcinoma versus other advanced solid tumours
Ciro Celsa, Giuseppe Cabibbo, Claudia A M Fulgenzi, et al.
Page
of 21